CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, the CML patients labeled clinically as imatinib responders and non-responders display significant differences in the frequencies of mutant BCR-ABL transcripts present in their pretreatment CD34+ cells [20], [35].